Equillium, Inc. (EQ) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Equillium reported revenue of $0, down 100.0% from $41.1M the year before. Net income was -$22.4M, or -$0.39 per diluted share. Operating activities generated -$22.7M of cash, leaving -$22.8M of free cash flow. At fiscal year end, Equillium held $31.9M in total assets against $3.3M in total liabilities, including $30.3M of cash and equivalents.
Open the full interactive Equillium financials → Quarterly statements, key ratios, valuation history and price charts.
Equillium Key Stats
| Share Price | $1.32 |
|---|---|
| Market Cap | $147.6M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.84 – $3.20 |
| Shares Outstanding | 111.8 million (basic, 2026 Q2) |
Equillium Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $15.8M | $36.1M | $41.1M | $0 |
| Operating Income | -$29.5M | -$37.8M | -$62.1M | -$14.5M | -$8.3M | -$23.6M |
| Pre-Tax Income | -$29.8M | -$39.1M | -$62.4M | -$12.8M | -$7.7M | -$22.4M |
| Income Tax | — | $0 | $0 | $580,000 | $361,000 | $0 |
| Net Income | -$29.8M | -$39.1M | -$62.4M | -$13.3M | -$8.1M | -$22.4M |
| Diluted EPS | -$1.46 | -$1.36 | -$1.85 | -$0.38 | -$0.23 | -$0.39 |
Equillium Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.2M | -$3.8M | -$5.3M | -$4.7M |
| Diluted EPS | -$0.06 | -$0.07 | -$0.06 | -$0.04 |
Equillium Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.0M | $50.4M | $59.1M | $23.2M | $18.1M | $30.3M |
| Current Assets | $85.2M | $83.4M | $76.7M | $49.3M | $25.0M | $31.0M |
| Total Assets | $85.4M | $85.4M | $78.4M | $50.5M | $25.6M | $31.9M |
| Current Liabilities | $7.2M | $8.9M | $32.0M | $27.6M | $6.4M | $2.9M |
| Total Long-Term Debt | $9.9M | $10.2M | $9.0M | — | — | — |
| Total Liabilities | $15.6M | $18.9M | $46.5M | $28.0M | $6.5M | $3.3M |
| Shareholders' Equity | $69.9M | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
Equillium Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$24.6M | -$32.1M | -$8.7M | -$21.8M | -$19.0M | -$22.7M |
| Cash From Investing | -$18.6M | $27.4M | $18.7M | -$4.8M | $13.8M | $4.5M |
| Cash From Financing | $53.9M | $31.1M | -$1.2M | -$9.2M | $164,000 | $30.4M |
| Free Cash Flow | -$24.8M | -$32.1M | -$9.0M | -$21.8M | -$19.1M | -$22.8M |
Figures from Equillium's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Equillium financials page for every line item.
Equillium Company Profile
| Ticker | EQ |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | La Jolla, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001746466 |
Frequently Asked Questions
What was Equillium's revenue in fiscal 2025?
Equillium (EQ) reported revenue of $0 for fiscal 2025.
What is Equillium's annual revenue history?
Equillium's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $15.8M; 2023: $36.1M; 2024: $41.1M; 2025: $0.
What was Equillium's net income in fiscal 2025?
Equillium reported net income of -$22.4M for fiscal 2025.
What was Equillium's earnings per share (EPS) in fiscal 2025?
Equillium's diluted EPS was -$0.39 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Equillium generate in fiscal 2025?
Equillium generated -$22.8M of free cash flow in fiscal 2025.
What was Equillium's revenue last quarter?
In its most recent reported quarter (2026 Q2), Equillium reported revenue of $0.
How many shares of Equillium are outstanding?
Equillium reported a weighted average of 111.8 million basic shares outstanding in 2026 Q2.
What is Equillium's market cap?
Based on its latest closing price, Equillium (EQ) has a market capitalization of about $147.6M.
When does Equillium's fiscal year end?
Equillium's fiscal year end, as registered with the SEC, is December 31.
Where is Equillium headquartered?
Equillium lists its business address in La Jolla, California in its SEC filings.